Related references
Note: Only part of the references are listed.Baseline comprehensive geriatric assessment (CGA) and prediction of toxicity in elderly non-small cell lung cancer (NSCLC) patients receiving chemotherapy.
A. Karampeazis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations
Yusuke Inoue et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies
Naoto Morikawa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients
Yen-Han Tseng et al.
ONCOLOGIST (2015)
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B. Besse et al.
ANNALS OF ONCOLOGY (2014)
Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology
A. G. Pallis et al.
ANNALS OF ONCOLOGY (2014)
Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer
Teppei Nishii et al.
BMC CANCER (2014)
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901
Kosuke Takahashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Polypharmacy and the management of the older cancer patient
L. Balducci et al.
ANNALS OF ONCOLOGY (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study
Kazunari Tateishi et al.
MEDICAL ONCOLOGY (2013)
Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Jose Rodrigues Pereira et al.
DRUGS IN R&D (2013)
Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
Shiro Fujita et al.
BMC CANCER (2012)
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score
Martine Extermann et al.
CANCER (2012)
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older
Yuh-Min Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study
Makoto Maemondo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano et al.
LANCET (2012)
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
Siow Ming Lee et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor
Kaoru Irisa et al.
MEDICAL ONCOLOGY (2012)
Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study
Kazuhiro Asami et al.
CLINICAL LUNG CANCER (2011)
Targeted anti-cancer therapy in the elderly
Wilson Gonsalves et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Phase II Study of Gefitinib as a First-line Therapy in Elderly Patients with Pulmonary Adenocarcinoma: West Japan Thoracic Oncology Group Study 0402
Masashi Kobayashi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Elisabeth Quoix et al.
LANCET (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know?
A. G. Pallis et al.
EUROPEAN JOURNAL OF CANCER (2010)
Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis
Hironori Uruga et al.
INTERNAL MEDICINE (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of national cancer institute of Canada clinical trials group trials
Timothy R. Asmis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2
Rogerio Lilenbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Paul Wheatley-Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naive Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer
Noriyuki Ebi et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition
Jean-Paul Sculier et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy
Ulrich Wedding et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
C. P. Belani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit
A Wilcock et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
F Cappuzzo et al.
BRITISH JOURNAL OF CANCER (2004)
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
C Gridelli et al.
BRITISH JOURNAL OF CANCER (2003)
Long-term trends in cancer mortality in the United States, 1930-1998
PA Wingo et al.
CANCER (2003)
Geriatric oncology: a clinical approach to the older patient with cancer
L Repetto et al.
EUROPEAN JOURNAL OF CANCER (2003)
Participation of patients 65 years of age or older in cancer clinical trials
JH Lewis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer
C Gridelli
ONCOLOGIST (2001)
Geriatric oncology: challenges for the new century
L Balducci
EUROPEAN JOURNAL OF CANCER (2000)
Assessment of the older cancer patient
M Extermann et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2000)
Share Paper
